Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Value Health Reg Issues ; 34: 14-22, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-36371899

RESUMO

OBJECTIVES: This study aims to synthesize health state utility values (HSUVs) of type 2 diabetes mellitus (T2DM) and its related complications published in the literature, conducting a meta-analysis of the data when possible. METHODS: We conducted a systematic search in MEDLINE and School of Health and Related Research Health Utilities Database repository. Studies focused on T2DM and its complications reporting utility values elicited using direct and indirect methods were selected. We categorized the results according to the instrument to describe health and meta-analyzed them accordingly. Data included in the analysis were pooled in a fixed-effect model by the inverse of variance mean and random-effects DerSimonian-Laird method. Two approaches on sensitivity analysis were performed: leave-one-out method and including data of HSUVs obtained by foreign population value sets. RESULTS: We identified 70 studies for the meta-analysis from a total of 467 studies. Sufficient data to pool T2DM HSUVs from EQ-5D instrument, hypoglycemia, and stroke were obtained. HSUVs varied from 0.7 to 0.92 in direct valuations, and the pooled mean of 3-level version of EQ-5D studies was 0.772 (95% confidence interval 0.763-0.78) and of 5-level version of EQ-5D 0.815 (95% confidence interval 0.808-0.823). HSUVs of complications varied from 0.739 to 0.843, or reductions of HSUVs between -0.014 and -0.094. In general, HSUVs obtained from 3-level version of EQ-5D and Health Utility Index 3 instruments were lower than those directly elicited. A considerable amount of heterogeneity was observed. Some complications remained unable to be pooled due to scarce of original articles. CONCLUSIONS: T2DM and its complications have a considerable impact on health-related quality of life. 5-level version of EQ-5D estimates seems comparable with direct elicited HSUVs.


Assuntos
Diabetes Mellitus Tipo 2 , Qualidade de Vida , Humanos
2.
Psychol Med ; 52(5): 914-923, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-32758314

RESUMO

BACKGROUND: Evidence suggests the incidence of non-affective psychotic disorders (NAPDs) varies across persons and places, but data from the Global South is scarce. We aimed to estimate the treated incidence of NAPD in Chile, and variance by person, place and time. METHODS: We used national register data from Chile including all people, 10-65 years, with the first episode of NAPD (International Classification of Diseases, Tenth Revision: F20-F29) between 1 January 2005 and 29 August 2018. Denominators were estimated from Chilean National Census data. Our main outcome was treated incidence of NAPD and age group, sex, calendar year and regional-level population density, multidimensional poverty and latitude were exposures of interest. RESULTS: We identified 32 358 NAPD cases [12 136 (39.5%) women; median age-at-first-contact: 24 years (interquartile range 18-39 years)] during 171.1 million person-years [crude incidence: 18.9 per 100 000 person-years; 95% confidence interval (CI) 18.7-19.1]. Multilevel Poisson regression identified a strong age-sex interaction in incidence, with rates peaking in men (57.6 per 100 000 person-years; 95% CI 56.0-59.2) and women (29.5 per 100 000 person-years; 95% CI 28.4-30.7) between 15 and 19 years old. Rates also decreased (non-linearly) over time for women, but not men. We observed a non-linear association with multidimensional poverty and latitude, with the highest rates in the poorest regions and those immediately south of Santiago; no association with regional population density was observed. CONCLUSION: Our findings inform the aetiology of NAPDs, replicating typical associations with age, sex and multidimensional poverty in a Global South context. The absence of association with population density suggests this risk may be context-dependent.


Assuntos
Transtornos Psicóticos , Adolescente , Adulto , Transtornos Psicóticos Afetivos , Chile/epidemiologia , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Pobreza , Transtornos Psicóticos/psicologia , Adulto Jovem
3.
Early Interv Psychiatry ; 15(5): 1104-1114, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-33047889

RESUMO

AIM: The evidence of the effectiveness and cost-effectiveness of early intervention for psychosis (EIP) services has motivated their implementation worldwide. However, complex interventions of such EIP services require local adaptations to successfully match population needs and cultural differences. Latin America is a heterogenous region where EIP services are progressively being adopted. Our aim is to map such initiatives in the region with a focus on implementation outcomes. METHODS: A scoping review following the Preferred Reporting Items for Systematic review and Meta-Analysis extension for Scoping Reviews guidelines was conducted. International and regional databases were searched for publications describing EIP programmes in the region. Besides mapping the services, we described implementation outcomes based on the Standards for Reporting Implementation Studies Checklist. RESULTS: Ten articles describing seven EIP initiatives from the region were found. Four countries were represented: Argentina, Brazil, Chile and Mexico. The implementation outcomes reporting was heterogenous, although it was possible to ascertain EIP services are feasible and adequate for the region's context. Also, there is some evidence of effectiveness in terms of reducing hospitalizations and improving symptoms. Information about fidelity measures was scarce and there was no information about costs or cost-effectiveness. CONCLUSIONS: Only a small proportion of Latin American countries have adopted EIP services. Although these programmes seem to be feasible and effective, data on other implementation outcomes, such as fidelity, cultural appropriateness, cost-effectiveness and affordability are not available. This might in part explain why this effective approach has not been yet scaled-up at nationwide levels.


Assuntos
Transtornos Psicóticos , Chile , Análise Custo-Benefício , Humanos , América Latina , Transtornos Psicóticos/diagnóstico , Transtornos Psicóticos/terapia
4.
Br J Psychiatry ; 215(1): 388-394, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-30696495

RESUMO

BACKGROUND: Early intervention in psychosis (EIP) has been developed as an approach to improve the prognosis of people with psychotic disorders and it has been claimed to be a more efficient model of care. However, the evidence is not definitive and doubts have spread regard to the economic outcomes of EIP services amid the usually restricted mental health budget.AimsWe aimed to review the cost-effectiveness evidence of EIP services worldwide. METHOD: We systematically reviewed the economic literature about EIP following the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement guidelines. Studies were selected according to previously stated criteria and analysed with standardised critical appraisal tools for trial-based economic evaluations and modelling studies. RESULTS: A total of 16 studies were selected after applying the eligibility criteria. Most of them were economic evaluations alongside clinical trials. The overall evidence was consistent in the cost-effectiveness of EIP compared with standard care for first episode of psychosis and the Clinical High Risk for Psychosis paradigm. Such evidence was replicated among different health systems, but mainly in high-income countries. The methodological quality of such evidence, however, was moderate and heterogeneity was significant across the studies. CONCLUSIONS: There is consistent evidence that the implementation of EIP services might be a cost-effective alternative across different health systems. Such evidence, nevertheless, derives from heterogeneous and sometimes methodologically flawed studies, reducing the certainty of such statement. More efforts must be done to rigorously assess the value of this intervention, before expanding it among systems where mental health budgets are more constrained.Declaration of interestNone.


Assuntos
Análise Custo-Benefício , Intervenção Médica Precoce , Transtornos Psicóticos/terapia , Humanos
5.
Medwave ; 17(Suppl1): e6845, 2017 Jan 19.
Artigo em Espanhol, Inglês | MEDLINE | ID: mdl-28112711

RESUMO

Art therapy is used as a complementary treatment to antipsychotics in schizophrenia. However, its effectiveness is not clear. To answer this question, we searched in Epistemonikos database, which is maintained by screening multiple databases. We identified five systematic reviews including 20 studies overall, of which four were randomized trials. We extracted data and prepared summary of findings tables using the GRADE method. We concluded it is not clear whether art therapy leads to clinical improvement in schizophrenia because the certainty of the evidence is very low.


La arteterapia se utiliza como tratamiento complementario a los antipsicóticos en la esquizofrenia, sin embargo, no está clara su efectividad. Para responder esta pregunta, se utilizó la base de datos Epistemonikos, la cual es mantenida mediante búsquedas en múltiples bases de datos. Identificamos cinco revisiones sistemáticas que en conjunto incluyen 20 estudios, de los cuales cuatro corresponden a estudios aleatorizados. Extrajimos los datos y preparamos tablas de resumen de los resultados utilizando el método GRADE. Concluimos que no está claro si la arteterapia produce mejoría en la esquizofrenia porque la certeza de la evidencia existente es muy baja.


Assuntos
Antipsicóticos/uso terapêutico , Arteterapia/métodos , Esquizofrenia/terapia , Terapia Combinada , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Esquizofrenia/fisiopatologia , Resultado do Tratamento
6.
Medwave ; 16(Suppl5): e6614, 2016 Dec 02.
Artigo em Espanhol, Inglês | MEDLINE | ID: mdl-27922589

RESUMO

Clozapine constitutes the treatment of choice in patients with schizophrenia with persisting symptoms despite antipsychotics at adequate dose and treatment duration. However, an important proportion does not respond to optimal doses of clozapine, so the addition of a second antipsychotic might increase clinical response. Searching in Epistemonikos database, which is maintained by screening multiple databases, we identified 17 systematic reviews comprising 62 studies addressing the question of this article, including 26 randomized trials. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded adding a second antipsychotic to clozapine in patients with refractory schizophrenia probably leads to little or no difference in clinical response, and increases adverse effects.


Assuntos
Antipsicóticos/administração & dosagem , Clozapina/administração & dosagem , Esquizofrenia/tratamento farmacológico , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Clozapina/efeitos adversos , Clozapina/uso terapêutico , Resistência a Medicamentos , Quimioterapia Combinada , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Esquizofrenia/fisiopatologia , Resultado do Tratamento
7.
Medwave ; 16(Suppl5): e6577, 2016 Oct 14.
Artigo em Espanhol, Inglês | MEDLINE | ID: mdl-27813505

RESUMO

Clozapine is considered to be the most effective antipsychotic drug for patients with treatment resistant schizophrenia, but up to a third of the patients do not respond to this treatment. Various strategies have been tried to augment the effect of clozapine in non-responders, one of these strategies being electroconvulsive therapy. However, its efficacy and safety are not yet clear. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified six systematic reviews including 55 studies, among them six randomized controlled trials addressing clozapine-resistant schizophrenia. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded electroconvulsive therapy probably augments response to clozapine in patients with treatment resistant schizophrenia, but it is not possible to determine if it leads to cognitive adverse effects because the certainty of the evidence is very low.


Assuntos
Clozapina/uso terapêutico , Eletroconvulsoterapia/métodos , Esquizofrenia/terapia , Antipsicóticos/uso terapêutico , Terapia Combinada , Resistência a Medicamentos , Eletroconvulsoterapia/efeitos adversos , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Esquizofrenia/fisiopatologia , Resultado do Tratamento
8.
Medwave ; 16 Suppl 2: e6447, 2016 May 23.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-27218484

RESUMO

Depot antipsychotics have been generally used in patients with chronic schizophrenia with adherence problems to oral therapy. However, it has been suggested they can be a good alternative in earlier stages too. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified three systematic reviews including two pertinent randomized trials. We combined the evidence using meta-analysis and generated a summary of findings table following the GRADE approach. We concluded it is not clear whether there are differences between depot and oral antipsychotics in first-episode psychosis because the certainty of the available evidence is very low.


Los antipsicóticos de depósito han sido utilizados generalmente en pacientes que padecen esquizofrenia crónica con problemas de adherencia a antipsicóticos orales. Sin embargo, se ha planteado que en etapas psicóticas precoces el uso de antipsicóticos de depósito podría ser más efectivo, aunque esto es materia de debate. Utilizando la base de datos Epistemonikos, la cual es mantenida mediante búsquedas en 30 bases de datos, identificamos tres revisiones sistemáticas que en conjunto incluyen dos estudios aleatorizados. Realizamos un metanálisis y tablas de resumen de los resultados utilizando el método GRADE. Concluimos que no está claro si los antipsicóticos de depósito son superiores o inferiores a los orales en un primer episodio psicótico porque la certeza de la evidencia disponible es muy baja.


Assuntos
Antipsicóticos/administração & dosagem , Transtornos Psicóticos/tratamento farmacológico , Esquizofrenia/tratamento farmacológico , Administração Oral , Preparações de Ação Retardada , Humanos , Adesão à Medicação , Transtornos Psicóticos/fisiopatologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Esquizofrenia/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA